WO2006047476A3 - Therapeutic and delivery methods of prostaglandin ep4 agonists - Google Patents

Therapeutic and delivery methods of prostaglandin ep4 agonists Download PDF

Info

Publication number
WO2006047476A3
WO2006047476A3 PCT/US2005/038303 US2005038303W WO2006047476A3 WO 2006047476 A3 WO2006047476 A3 WO 2006047476A3 US 2005038303 W US2005038303 W US 2005038303W WO 2006047476 A3 WO2006047476 A3 WO 2006047476A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostaglandin
agonists
therapeutic
prodrug
disclosed
Prior art date
Application number
PCT/US2005/038303
Other languages
French (fr)
Other versions
WO2006047476A2 (en
Inventor
Wha Bin Im
Yariv Donde
Mark Holoboski
David W Old
Karen M Kedzie
Daniel W Gil
John E Donello
Robert M Burk
Todd S Gac
Original Assignee
Allergan Inc
Wha Bin Im
Yariv Donde
Mark Holoboski
David W Old
Karen M Kedzie
Daniel W Gil
John E Donello
Robert M Burk
Todd S Gac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Wha Bin Im, Yariv Donde, Mark Holoboski, David W Old, Karen M Kedzie, Daniel W Gil, John E Donello, Robert M Burk, Todd S Gac filed Critical Allergan Inc
Priority to JP2007539030A priority Critical patent/JP2008518013A/en
Priority to US11/574,528 priority patent/US20080132543A1/en
Priority to AU2005299473A priority patent/AU2005299473B2/en
Priority to CA002585367A priority patent/CA2585367A1/en
Priority to EP05817142A priority patent/EP1805139A2/en
Priority to BRPI0518242-5A priority patent/BRPI0518242A2/en
Publication of WO2006047476A2 publication Critical patent/WO2006047476A2/en
Publication of WO2006047476A3 publication Critical patent/WO2006047476A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A compound comprising a prodrug of a prostaglandin EP4 agonist, wherein said prodrug is an ester, ether, or amide of a carbohydrate; or said prodrug is an ester, ether, or amide of an amino acid is disclosed herein. Maintenance of the colonic mucosal barrier by method comprising administering a therapeutically effective amount of a prostaglandin EP4 agonist to a colon of a mammal is also disclosed herein. Dosage forms, medicaments, and compositions, related thereto are also disclosed.
PCT/US2005/038303 2004-10-26 2005-10-24 Therapeutic and delivery methods of prostaglandin ep4 agonists WO2006047476A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2007539030A JP2008518013A (en) 2004-10-26 2005-10-24 Treatment method and delivery method with prostaglandin EP4 agonist
US11/574,528 US20080132543A1 (en) 2004-10-26 2005-10-24 Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists
AU2005299473A AU2005299473B2 (en) 2004-10-26 2005-10-24 Therapeutic and delivery methods of prostaglandin EP4 agonists
CA002585367A CA2585367A1 (en) 2004-10-26 2005-10-24 Therapeutic and delivery methods of prostaglandin ep4 agonists
EP05817142A EP1805139A2 (en) 2004-10-26 2005-10-24 Therapeutic and delivery methods of prostaglandin ep4 agonists
BRPI0518242-5A BRPI0518242A2 (en) 2004-10-26 2005-10-24 Therapeutic and release methods of prostaglandin ep4 agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62242204P 2004-10-26 2004-10-26
US60/622,422 2004-10-26

Publications (2)

Publication Number Publication Date
WO2006047476A2 WO2006047476A2 (en) 2006-05-04
WO2006047476A3 true WO2006047476A3 (en) 2006-09-28

Family

ID=35840538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/038303 WO2006047476A2 (en) 2004-10-26 2005-10-24 Therapeutic and delivery methods of prostaglandin ep4 agonists

Country Status (7)

Country Link
US (1) US20080132543A1 (en)
EP (1) EP1805139A2 (en)
JP (1) JP2008518013A (en)
AU (1) AU2005299473B2 (en)
BR (1) BRPI0518242A2 (en)
CA (1) CA2585367A1 (en)
WO (1) WO2006047476A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005304764B2 (en) * 2004-11-08 2012-07-12 Allergan, Inc. Substituted pyrrolidone compounds as EP4 agonists
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
JP2010513551A (en) * 2006-12-18 2010-04-30 アラーガン インコーポレイテッド Gastrointestinal treatment methods and compositions
WO2010108028A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
EP2488168A1 (en) 2009-10-14 2012-08-22 Gemmus Pharma Inc. Combination therapy treatment for viral infections
CN112516167A (en) 2010-08-12 2021-03-19 菲特治疗公司 Improved hematopoietic stem and progenitor cell therapy
US20120259413A1 (en) * 2011-04-07 2012-10-11 Allergan, Inc. Devices, compositions and methods utilizing ep4 and ep2 receptor agonists for preventing, reducing or treating capsular contracture
KR102011532B1 (en) 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. Compounds for improved viral transduction
PT2785834T (en) 2011-12-02 2020-11-13 Fate Therapeutics Inc Enhanced stem cell composition
US10111907B2 (en) 2011-12-02 2018-10-30 Fate Therapeutics, Inc. Methods of treating ischemia
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
CN105979959B (en) 2013-08-09 2021-11-30 阿德利克斯公司 Compounds and methods for inhibiting phosphate transport
EP3413896B1 (en) 2016-02-12 2021-03-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
RU2021103425A (en) 2016-02-12 2021-02-25 Блубёрд Био, Инк. COMPOSITIONS INCREASING THE NUMBER OF VECTOR COPIES (VECTOR COPIES) AND METHODS OF THEIR APPLICATION
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5052047A (en) * 1973-07-12 1975-05-09
EP0287036A2 (en) * 1987-04-13 1988-10-19 Ono Pharmaceutical Co., Ltd. New pharmaceutical compositions comprising esters or amides as active ingredients
EP0985663A1 (en) * 1998-04-16 2000-03-15 Ono Pharmaceutical Co., Ltd. A 3.7-dithiaprostanoic acid derivative
EP1097922A1 (en) * 1998-07-15 2001-05-09 Ono Pharmaceutical Co., Ltd. 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
WO2003009872A1 (en) * 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
US6538018B1 (en) * 2001-06-14 2003-03-25 Allergan, Inc. 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US6586468B1 (en) * 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1476429A (en) * 2000-11-27 2004-02-18 �Ʒ� EP4 receptor selective agonists in treatment of osteoporosis
CA2451392A1 (en) * 2001-07-16 2003-01-30 F. Hoffmann-La Roche Ag Prostaglandin analogues as ep4 receptor agonists
ES2268327T3 (en) * 2002-03-18 2007-03-16 Pfizer Products Inc. USE OF A SELECTIVE OF AN EP4 RECEIVER FOR THE TREATMENT OF DISEASES.
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (en) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
KR101077461B1 (en) * 2003-02-11 2011-10-26 알러간, 인코포레이티드 1010- 1010-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5052047A (en) * 1973-07-12 1975-05-09
EP0287036A2 (en) * 1987-04-13 1988-10-19 Ono Pharmaceutical Co., Ltd. New pharmaceutical compositions comprising esters or amides as active ingredients
EP0985663A1 (en) * 1998-04-16 2000-03-15 Ono Pharmaceutical Co., Ltd. A 3.7-dithiaprostanoic acid derivative
EP1097922A1 (en) * 1998-07-15 2001-05-09 Ono Pharmaceutical Co., Ltd. 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
US6586468B1 (en) * 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
US6538018B1 (en) * 2001-06-14 2003-03-25 Allergan, Inc. 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US20040102499A1 (en) * 2001-06-14 2004-05-27 Allergan, Inc. EP4 agonists as agents for lowering intraocular pressure
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
WO2003009872A1 (en) * 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
EP1417975A1 (en) * 2001-07-23 2004-05-12 Ono Pharmaceutical Co., Ltd. REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AKAMATSU K ET AL: "SYNTHESIS AND BIODISTRIBUTION STUDY OF LIVER-SPECIFIC PROSTAGLANDINE1 POLYMERIC CONJUGATE", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 155, no. 1, 1997, pages 65 - 74, XP002926547, ISSN: 0378-5173 *
ANDERSON, BRADLEY D. ET AL: "Prostaglandin prodrugs . VI: Structure-thermodynamic activity and structure-aqueous solubility relationships", JOURNAL OF PHARMACEUTICAL SCIENCES , 69(4), 424-30 CODEN: JPMSAE; ISSN: 0022-3549, 1980, XP008060923 *
CHOURASIA M K ET AL: "Polysaccharides for Colon Targeted Drug Delivery", DRUG DELIVERY: JOURNAL OF DELIVERY AND TARGETING OF THERAPEUTIC AGENTS 2004 UNITED STATES, vol. 11, no. 2, 2004, pages 129 - 148, XP008060983, ISSN: 1071-7544 *
DATABASE WPI Section Ch Derwent World Patents Index; Class B05, AN 1975-61200W, XP002370551 *
FRIEND D R ET AL: "COLON-SPECIFIC DRUG DELIVERY FROM A GLUCOSIDE PRODRUG IN THE GUINEA-PIG. EFFICACY STUDY", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 15, no. 1, February 1991 (1991-02-01), pages 47 - 54, XP000200509, ISSN: 0168-3659 *
KABASHIMA K ET AL: "The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut", JOURNAL OF CLINICAL INVESTIGATION 2002 UNITED STATES, vol. 109, no. 7, 2002, pages 883 - 893, XP002370491, ISSN: 0021-9738 *
KAJINO HIROKI ET AL: "An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo", PEDIATRIC RESEARCH, vol. 56, no. 4, October 2004 (2004-10-01), pages 586 - 590, XP002370490, ISSN: 0031-3998 *
MARUYAMA T ET AL: "DESIGN AND SYNTHESIS OF A SELECTIVE EP4-RECEPTOR AGONIST. PART 4: PRACTICAL SYNTHESIS AND BIOLOGICAL EVALUTION OF A NOVEL HIGHLY SELECTIVE EP4-RECEPTOR AGONIST", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 10, 2002, pages 2103 - 2110, XP001222023, ISSN: 0968-0896 *
YOSHIDA K ET AL: "Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 02 APR 2002 UNITED STATES, vol. 99, no. 7, 2 April 2002 (2002-04-02), pages 4580 - 4585, XP002370559, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2585367A1 (en) 2006-05-04
WO2006047476A2 (en) 2006-05-04
AU2005299473B2 (en) 2012-06-28
JP2008518013A (en) 2008-05-29
BRPI0518242A2 (en) 2008-11-11
US20080132543A1 (en) 2008-06-05
EP1805139A2 (en) 2007-07-11
AU2005299473A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
WO2006047476A3 (en) Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2009092073A3 (en) Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
MY139577A (en) Anti-inflammatory androstane derivative
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2007145991A3 (en) Anti-inflammatory and analgesic compositions and related methods
MX2010006284A (en) Phenylephrine pharmaceutical formulations and compositions for transmucosal absorption.
MX356032B (en) Indole compounds and methods for treating visceral pain.
WO2008063300A8 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
RS53155B (en) Administration of dipeptidyl peptidase inhibitors
WO2007106550A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
NO20072767L (en) Gabapentin prodrug sustained release oral dosage forms
PT1718288E (en) Solid formulations of ospemifene
WO2011007247A8 (en) Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
WO2008011116A3 (en) Aza-peptide protease inhibitors
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
WO2009158625A3 (en) Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2011036521A3 (en) Formulations comprising triptan compounds
WO2008144269A3 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
WO2007134241A3 (en) Nasal delivery of therapeutic agents using tight junction agonists
WO2008011117A3 (en) Antiviral protease inhibitors
WO2004064758A3 (en) Improved oral delivery of peptides
WO2009015485A8 (en) Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REEP Request for entry into the european phase

Ref document number: 2005817142

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005817142

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2585367

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005299473

Country of ref document: AU

Ref document number: 2007539030

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005299473

Country of ref document: AU

Date of ref document: 20051024

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005817142

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11574528

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0518242

Country of ref document: BR